Pharmacologic Management of Urinary Frequency with Normal Urinalysis

First-Line Treatment Requirement

Behavioral therapies should be offered first as they are equally effective as antimuscarinic medications for reducing symptom levels and carry no risk of adverse effects, according to the American Urological Association 1, 2
Behavioral interventions include bladder training, bladder control strategies, pelvic floor muscle training, and fluid management, as recommended by the American Urological Association 1, 2
However, behavioral therapies may be combined with pharmacologic management simultaneously if the patient has moderate to severe symptoms, as suggested by the American Urological Association 4, 5

The American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guidelines recommend offering oral antimuscarinics as second-line therapy, with no compelling evidence for differential efficacy across medications 1, 2
Mirabegron is an effective alternative with a different mechanism of action and lower anticholinergic side effect profile, according to the American College of Physicians 7, 4, 5
Mirabegron achieved continence more than placebo (NNTB 12) and improved urinary incontinence (NNTB 9) with moderate-quality evidence, as reported by the American College of Physicians 7

For patients concerned about side effects, particularly elderly patients, tolterodine or darifenacin should be preferred, as recommended by the American Geriatrics Society 6
Tolterodine has discontinuation rates due to adverse effects similar to placebo with high-quality evidence, according to the American College of Physicians 8, 6
Solifenacin is associated with the lowest risk for discontinuation due to adverse effects among antimuscarinics (NNTB 9 for achieving continence), as reported by the American College of Physicians 8, 6

Antimuscarinics should not be used in patients with narrow-angle glaucoma unless approved by an ophthalmologist, and should be used with extreme caution in patients with impaired gastric emptying, history of urinary retention, or patients taking 7 or more concomitant medications, as warned by the American Urological Association 1, 2, 3
The 2024 American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline requires discussing the potential risk for developing dementia and cognitive impairment with all patients prescribed antimuscarinic medications 3

Confirm diagnosis: Urinary frequency with normal UA suggests overactive bladder symptoms, as defined by the American Urological Association 1, 2
Initiate behavioral therapies first (bladder training, fluid management, pelvic floor exercises), as recommended by the American Urological Association 1, 2
If behavioral therapy inadequate or patient has moderate-to-severe symptoms, add pharmacologic therapy, starting with mirabegron 25-50 mg once daily, tolterodine 2 mg twice daily, or darifenacin, as suggested by the American Urological Association 3, 4, 5

Do not prescribe antimuscarinics without discussing dementia risk, especially for chronic use, as warned by the American Urological Association 3
Do not use higher doses of solifenacin (10 mg) initially as they increase adverse effects without improving efficacy, as reported by the American College of Physicians 7, 8
Do not abandon antimuscarinic therapy after one medication fails - patients may respond better to a different agent or dose modification, as suggested by the American Urological Association 4, 5